Deloitte January 9, 2024

Explore our 2024 life sciences M&A predictions

Life sciences M&A was a bright spot across the wider dealmaking world in 2023. Will this positive trend continue over the next 12 months? We think so. We’re making five bold 2024 life sciences M&A predictions, which include another strong year for pharma M&A and a positive turn for the MedTech market. Find out what...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
STAT+: The biotech scorecard for the first quarter: 16 stock-moving events to watch
Pharma Pulse 1/6/25: The Future of RFID and Supply Chain Management, Optimizing IBD Management & more
How Biopharma BD&L Teams are Enhancing Decision Support Capabilities
Navigating future biopharma catalysts: What to expect at the 2025 J.P. Morgan Healthcare Conference
5 Healthcare Predictions for 2025 from One VC Firm

Share This Article